Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study

M Suenaga, N Mizunuma, S Matsusaka… - Drug design …, 2015 - Taylor & Francis
Background The effectiveness of reintroducing oxaliplatin in patients with metastatic
colorectal cancer refractory to standard chemotherapy has not been verified. We performed …
被引用次数：58 相关文章

Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study

M Suenaga, N Mizunuma… - Drug design …, 2015 - pubmed.ncbi.nlm.nih.gov
Background The effectiveness of reintroducing oxaliplatin in patients with metastatic
colorectal cancer refractory to standard chemotherapy has not been verified. We performed …

Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study

M Suenaga, N Mizunuma, S Matsusaka… - Drug Design …, 2015 - dovepress.com
Background: The effectiveness of reintroducing oxaliplatin in patients with metastatic
colorectal cancer refractory to standard chemotherapy has not been verified. We performed …
[PDF] academia.edu

[PDF][PDF] Phase ii study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: re-OPen study

M Ozaka, M Ogura, T Yamaguchi - Drug Design, Development and …, 2015 - academia.edu
Background: The effectiveness of reintroducing oxaliplatin in patients with metastatic
colorectal cancer refractory to standard chemotherapy has not been verified. We performed …
[PDF] semanticscholar.org

[PDF][PDF] Phase ii study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: re-OPen study

M Ozaka, M Ogura… - Drug Design …, 2015 - pdfs.semanticscholar.org
Background: The effectiveness of reintroducing oxaliplatin in patients with metastatic
colorectal cancer refractory to standard chemotherapy has not been verified. We performed …
[HTML] nih.gov

[HTML][HTML] Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study

M Suenaga, N Mizunuma, S Matsusaka… - Drug Design …, 2015 - ncbi.nlm.nih.gov
Background The effectiveness of reintroducing oxaliplatin in patients with metastatic
colorectal cancer refractory to standard chemotherapy has not been verified. We performed …

Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study

M Suenaga, N Mizunuma, S Matsusaka… - Drug Design …, 2015 - go.gale.com
Background: The effectiveness of reintroducing oxaliplatin in patients with metastatic
colorectal cancer refractory to standard chemotherapy has not been verified. We performed …

Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study.

M Suenaga, N Mizunuma, S Matsusaka… - Drug Design …, 2015 - europepmc.org
Background The effectiveness of reintroducing oxaliplatin in patients with metastatic
colorectal cancer refractory to standard chemotherapy has not been verified. We performed …

Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study

M Suenaga, N Mizunuma, S Matsusaka… - Drug Design …, 2015 - search.proquest.com
Background: The effectiveness of reintroducing oxaliplatin in patients with metastatic
colorectal cancer refractory to standard chemotherapy has not been verified. We performed …
[PDF] researchgate.net

[PDF][PDF] Phase ii study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: re-OPen study

M Ozaka, M Ogura, T Yamaguchi - Drug Design, Development …, 2015 - researchgate.net
Background: The effectiveness of reintroducing oxaliplatin in patients with metastatic
colorectal cancer refractory to standard chemotherapy has not been verified. We performed …